Download - Lundbeck

Lundbeck Magazine 2009
47
Cipralex/Lexapro® (escitalopram)
Approved for:
Depression and anxiety
Launch year:
2002
Partner:
Forest Laboratories, Inc. (USA)
Azilect® (rasagilin)
Approved for:
Parkinson’s disease
Launch year: 2005
Partner:
Teva Pharmaceutical
Industries Ltd.
Ebixa® (memantin)
Approved for:
Alzheimer’s disease
Launch year:
2002
Partner:
Merz Pharmaceuticals GmbH
Serdolect® (sertindol)
Approved for:
Schizophrenia
Launch year:
2006
Circadin®
Approved for:
Insomnia
Launch year:
2008
Partner: Neurim
Pharmaceuticals Ltd.
Revenue per product 2008
16%
1%
2%
14%
22%
2%
43%
Cipralex®
Lexapro®
Ebixa®
Azilect®
Serdolect®
Other
pharmaceuticals
Other revenue
Revenue DKK 11,282 million
Research and development costs DKK 2,992 million
Profit from operations DKK 2,352 million
Net profit for the year DKK 1,510 million
Pharmaceuticals in clinical development
Development stage Registration
Indication I Compound Phase I Phase II Phase III application
Employees by business area 2008
2,500
2,000
1,500
1,000
500
0
Production
Research & Sales &
development marketing
Europe USA Other
Administration
Schizophrenia I Serdolect® USA
Depression/angst I Lu AA21004 2010
Schizophrenia I Bifeprunox 2011
Alchol dependence I Nalmefen 2011
Stroke I Desmoteplase 2011+
Psychosis I Lu 31-130 2011+
Depression I Lu AA24530 2011+
Depression/bipolar disorder I Lu AA34893 2011+
Psychosis I Lu AE58054 2011+
Psychosis/bipolar disorderI Lu AA39959 2011+
Stroke/neuronal damage I Lu AA24493 2011+
Neurological diseases I Lu AA38466 2011+